Provectus Biopharmaceuticals approved the conversion of $542,500 in accrued directors' fees into Series D-1 Preferred Stock. The conversion price is $2.862 per share, resulting in 189,554 preferred shares that are convertible into 1,895,540 common shares. The move settles outstanding cash compensation owed to board members.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding PROVECTUS BIOPHARMACEUTICA-A (PVCT)?

Major stakeholders currently include Home Federal Bank Of Tennessee ($5.1K), Wealth Preservation Advisors, LLC ($2.7K), Atlas Wealth LLC ($999.0). Based on the latest 13F filings, there are a total of 5 tracked investment funds and institutions maintaining positions in PVCT.

What is the overall institutional sentiment toward PVCT recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $247.0, driven by 1 managers accumulating shares while 0 reduced their exposure.

Which institutions have been selling or reducing their PVCT positions?

In the latest period, no tracked funds trimmed or exited their positions in PVCT.

Are there any notable investors adding PVCT to their portfolios?

Yes, buying activity remains notable. 1 institutions opened new positions in {ticker}, and 0 existing holders added to their shares. The total reported buy value for the quarter amounted to $999.0.